Vanguard Group sells shares of 7 companies worth Rs 998 cr
US-based financial services company Vanguard Group on Friday bought shares of seven companies including Concord Biotech, Five-Star Business Finance and Marksans Pharma for Rs 998 crore through open ma
Vanguard Group Acquires Rs 998 Crore in Indian Companies
US-based financial services company Vanguard Group acquired shares worth Rs 998 crore in seven Indian companies via open market transactions on the NSE. Concurrently, Zurich-based UBS Group AG sold shares worth Rs 479.
UBS sells shares worth Rs 480 crore in Concord Biotech, IIFL Securities, 2 more stocks via block deals
UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, totaling Rs 480 crore. The largest sale was in Concord Biotech, worth Rs 192 crore at a 15% premium.
Vanguard Group Buys Rs 998 Cr Shares in 7 Companies
Vanguard Group, a US-based financial services company, has purchased shares in seven Indian companies, including Concord Biotech and Five-Star Business Finance, for a total of Rs 998 crore.
Vanguard sells shares of 7 companies worth Rs 998 cr via block deals
US-based financial services company Vanguard Group on Friday bought shares of seven companies including Concord Biotech, Five-Star Business Finance and Marksans Pharma for Rs 998 crore through open market transactions.
Bulk deals : Vanguard Group buys shares worth Rs 1000 crore in 7 companies
On September 20, The Vanguard Group Inc A/C Vanguard Total International Stock Index Fund, The Vanguard Group Inc A/C Vanguard Emerging Markets Stock Index Fund A Series of Vanguard International, and UBS Principal Capital Asia Limited bought and sold stakes in various companies via bulk deals.
UBS Offloads Shares Worth Rs 480 Crore In Four Companies
UBS Principal Capital Asia Ltd. sold stakes in Concord Biotech Ltd., Five-Star Bus Fin Ltd., IIFL Securities Ltd. and Marksans Pharma Ltd. worth Rs 480 crore, according to the bulk deal data on the NSE. Concord had 7.4 lakh shares sold by UBS, representing a 0.7% stake at Rs 2589.86 apiece, aggregating to a total value of 191 crore.
Wall Street Journal4d
Marksans Pharma Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Morningstar2d
Marksans Pharma Ltd
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Stock market update: Nifty Pharma index advances 0.33%
Benchmark NSE Nifty50 index ended up 375.16 points at 25790.95, while the BSE Sensex stood up 1359.51 points at 84544.31.
moneycontrol.com29d
Marksans Pharma Consolidated June 2024 Net Sales at Rs 590.62 crore, up 18.12% Y-o-Y
Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on ...